Freenome (NASDAQ:FRNM) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Freenome (NASDAQ:FRNM) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $18.00.

FRNM has been the topic of a number of analyst reports. Leerink Partners started coverage on shares of Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Guggenheim assumed coverage on Freenome in a research note on Thursday, August 20th. They set a “buy” rating and a $21.00 price target for the company. Jefferies Financial Group began coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 price target for the company. TD Cowen began coverage on Freenome in a report on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective for the company. Finally, Weiss Ratings initiated coverage on Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating for the company.

Freenome Price Performance

Shares of NASDAQ FRNM opened at $12.64 on Wednesday. The firm’s 50-day simple moving average is $15.14. The firm has a market capitalization of $1.36 billion, a PE ratio of -210.63 and a beta of 0.44. Freenome has a 1 year low of $9.97 and a 1 year high of $17.50.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at early stages. The company combines artificial intelligence, machine learning and multi-omic analysis of blood samples to identify biological signals associated with cancer, including signals from tumors and the immune system.

Freenome’s primary focus has been the development of noninvasive screening tests for colorectal cancer and other common cancers. Its platform is intended to support earlier detection through routine blood draws, with colorectal cancer screening among the company’s most advanced areas of development.